DexCom (NASDAQ:DXCM) PT Raised to $172.00

DexCom (NASDAQ:DXCM) had its target price lifted by Raymond James from $150.00 to $172.00 in a research note published on Thursday morning, 24/7 WallStreet reports. Raymond James currently has an outperform rating on the medical device company’s stock.

DXCM has been the subject of a number of other research reports. Piper Jaffray Companies increased their price target on shares of DexCom from $173.00 to $182.00 and gave the company a positive rating in a report on Wednesday, July 31st. BMO Capital Markets increased their price target on shares of DexCom from $167.00 to $172.00 and gave the company an outperform rating in a report on Thursday, May 2nd. Canaccord Genuity increased their price target on shares of DexCom from $160.00 to $185.00 and gave the company a buy rating in a report on Thursday. UBS Group lowered their price target on shares of DexCom from $150.00 to $140.00 and set a neutral rating for the company in a report on Tuesday, April 30th. Finally, BTIG Research reaffirmed a hold rating on shares of DexCom in a report on Thursday. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $163.71.

Shares of DexCom stock traded down $2.64 during trading on Thursday, reaching $141.57. 7,762 shares of the stock traded hands, compared to its average volume of 853,906. The firm has a market cap of $13.15 billion, a P/E ratio of 468.67 and a beta of 0.80. The firm’s fifty day moving average price is $149.93. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 6.75. DexCom has a 52-week low of $105.05 and a 52-week high of $161.30.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.07. The firm had revenue of $336.40 million during the quarter, compared to analyst estimates of $304.40 million. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The business’s quarterly revenue was up 38.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) earnings per share. On average, sell-side analysts predict that DexCom will post 0.94 EPS for the current year.

In other DexCom news, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $116.92, for a total value of $46,768.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $115.73, for a total transaction of $694,380.00. The disclosure for this sale can be found here. In the last three months, insiders sold 63,065 shares of company stock valued at $8,207,313. 0.88% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in DXCM. Gradient Investments LLC bought a new stake in DexCom in the second quarter worth about $25,000. Steward Partners Investment Advisory LLC bought a new stake in DexCom in the second quarter worth about $31,000. Private Ocean LLC bought a new stake in DexCom in the first quarter worth about $36,000. Wealthcare Advisory Partners LLC bought a new stake in DexCom in the second quarter worth about $37,000. Finally, Canton Hathaway LLC bought a new stake in shares of DexCom during the first quarter valued at approximately $41,000. 96.21% of the stock is owned by institutional investors and hedge funds.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: What are catch-up contributions?

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.